AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia
复制标题
DOI：
10.1182/blood-2013-04-495366
复制
发表时间：
2014-02-06
期刊：
影响因子：
20.3
通讯作者：
Huszar, Dennis
中科院分区：
文献类型：
--
作者：
Keeton, Erika K.;McEachern, Kristen;Huszar, Dennis
在几种类型的白血病和淋巴瘤中观察到 Pim 激酶的上调。 Pim-1、-2 和 -3 促进细胞因子和生长因子信号通路下游的细胞增殖和存活。 AZD1208 是一种有效的、高选择性的、口服的 Pim 激酶抑制剂，可有效抑制所有三种异构体
Upregulation of Pim kinases is observed in several types of leukemias and lymphomas. Pim-1, -2, and -3 promote cell proliferation and survival downstream of cytokine and growth factor signaling pathways. AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor that effectively inhibits all three isoforms at